Corcept Therapeutics - CORT Stock Forecast, Price & News

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. StockNews.com cut Corcept Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, August 5th. Truist Financial lowered Corcept Therapeutics to a "hold" rating in a research report on Tuesday, August 9th. HC Wainwright raised their price objective on Corcept Therapeutics from $29.00 to $33.00 and gave the company a "buy" rating in a research report on Thursday, August 4th. Finally, Jefferies Financial Group raised Corcept Therapeutics from a "hold" rating to a "buy" rating and raised their price objective for the company from $21.00 to $35.00 in a research report on Wednesday, July 27th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $32.00.

Corcept Therapeutics Price Performance

CORT Stock traded down $0.34 on Monday, reaching $28.07. 515,487 shares of the company traded hands, compared to its average volume of 857,244. The company has a market cap of $3.01 billion, a P/E ratio of 30.22, a price-to-earnings-growth ratio of 2.86 and a beta of 0.51. The firm has a fifty day simple moving average of $25.43 and a 200-day simple moving average of $23.25. Corcept Therapeutics has a one year low of $15.82 and a one year high of $29.93.

Insiders Place Their Bets

In other Corcept Therapeutics news, insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction on Monday, July 18th. The stock was sold at an average price of $27.37, for a total value of $684,250.00. Following the completion of the sale, the insider now owns 40,024 shares of the company's stock, valued at approximately $1,095,456.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Corcept Therapeutics news, insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction on Monday, July 18th. The stock was sold at an average price of $27.37, for a total value of $684,250.00. Following the completion of the sale, the insider now owns 40,024 shares of the company's stock, valued at approximately $1,095,456.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Gary Charles Robb sold 45,000 shares of Corcept Therapeutics stock in a transaction on Wednesday, July 6th. The stock was sold at an average price of $26.00, for a total value of $1,170,000.00. Following the completion of the sale, the insider now directly owns 24,123 shares of the company's stock, valued at approximately $627,198. The disclosure for this sale can be found here. In the last quarter, insiders sold 384,980 shares of company stock valued at $9,895,043. Corporate insiders own 18.60% of the company's stock.